echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JCO: Can recurrent ovarian cancer benefit from carboplatin intraperitoneal hyperthermic perfusion chemotherapy during secondary cytoreductive surgery?

    JCO: Can recurrent ovarian cancer benefit from carboplatin intraperitoneal hyperthermic perfusion chemotherapy during secondary cytoreductive surgery?

    • Last Update: 2021-05-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In 2021, the United States is expected to add 21,410 new cases of ovarian cancer , and about 13,770 women will die of ovarian cancer.


    Ovarian cancer

    This study aimed to evaluate the efficacy of carboplatin hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) in patients with recurrent ovarian cancer during secondary cytoreductive surgery .


    This study aims to evaluate the efficacy of carboplatin intraperitoneal hyperthermic perfusion chemotherapy (HIPEC) in patients with recurrent ovarian cancer during secondary cytoreductive surgery.


    98 subjects randomly received carboplatin HIPEC (HIPEC group, 800 mg/m2, for 90 minutes) or no HIPEC (standard treatment group) intraoperatively.


    A total of 98 patients, 49 in each group.


    There were no perioperative deaths, and there were no differences in the use of ostomy, hospital stay or postoperative toxicity between the two groups.


    At 24 months, 8 patients in the HIPEC group did not progress or died, while 12 patients in the standard treatment group

    PFS and OS of the two groups

    PFS and OS of the two groups

    During the mid-term follow-up of 39.


    The median HIPEC group and the standard treatment group progression-free survival was 12.


    Carboplatin for intraperitoneal hyperthermic infusion chemotherapy is well tolerated in patients with recurrent ovarian cancer, but it does not produce a good clinical prognosis

    Original source:

    Original source:

    Oliver Zivanovic, et al.


    org/10.
    1200/JCO.
    21.
    00605" target="_blank" rel="noopener">Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.